Carbimazole

Carbimazole
Clinical data
Trade namesNeo-Mercazole, Anti-Thyrox, etc.
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding85%
Elimination half-life5.3h
ExcretionKidney >90%
Identifiers
  • ethyl 3-methyl-2-sulfanylidene-imidazole-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.040.762 Edit this at Wikidata
Chemical and physical data
FormulaC7H10N2O2S
Molar mass186.23 g·mol−1
3D model (JSmol)
Melting point122 to 125 °C (252 to 257 °F)
  • S=C1N(\C=C/N1C(=O)OCC)C
  • InChI=1S/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3 checkY
  • Key:CFOYWRHIYXMDOT-UHFFFAOYSA-N checkY
  (verify)

Carbimazole (brand names Neo-Mercazole, Anti-Thyrox, etc.) is used to treat hyperthyroidism. Carbimazole is a pro-drug as after absorption it is converted to the active form, methimazole. Methimazole prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of the thyroid hormones T3 and T4 (thyroxine).

It is on the World Health Organization's List of Essential Medicines.[2]

  1. ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
  2. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.